Letter: nutritional benefits of rifaximin in cirrhotic patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|5|699-700

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.5, 2018-03, pp. : 699-700

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: the efficacy and safety of rifaximin for the prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 697-698

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: proton pump inhibitor treatment and increased mortality in cirrhotic patients

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 11, 2015-06 ,pp. : 1224-1224

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: proton pump inhibitor treatment and increased mortality in cirrhotic patients – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 11, 2015-06 ,pp. : 1225-1225

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: what else can improve survival in cirrhotic patients with spontaneous bacterial peritonitis and associated septic shock? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 1, 2015-07 ,pp. : 123-124

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: what else can improve survival in cirrhotic patients with spontaneous bacterial peritonitis and associated septic shock?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 1, 2015-07 ,pp. : 123-123

John Wiley & Sons Inc

Access to resources Recommend Favorite